A heated clash over drug pricing is unfolding this week in Canada where Alexion Pharmaceuticals is challenging how the government attempts to control excessive prices.

The battle is actually the latest round in a long-running drama between the drug maker and the Patented Medicine Review Board, which successfully argued Alexion overcharged for Soliris, a medicine that is used to treat a pair of rare diseases. The drug costs either $380,000 or $585,000 in US dollars, depending upon the ailment being treated, and some provincial governments have declined coverage.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy